Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data i...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2017-11, Vol.102 (5), p.765-776
Main Authors: Verheijen, Remy B., Yu, Huixin, Schellens, Jan H.M., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D.R.
Format: Article
Language:English
Subjects:
Dose-Response Relationship, Drug
Drug Monitoring - methods
Drug Monitoring - standards
Humans
Medical Oncology - methods
Medical Oncology - standards
Neoplasms - drug therapy
Neoplasms - enzymology
Practice Guidelines as Topic - standards
Prospective Studies
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Reviews
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.787